Phaseline

Companies › Cell Biopeutics Resources Sdn Bhd

Cell Biopeutics Resources Sdn Bhd: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 4; Cardiovascular; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Stempeucel®
Ex-vivo cultured allogeneic mesenchymal stem cells (MSCs)
–Phase 4Critical Limb IschemiaOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05854641Stempeucel®Phase 4Critical Limb IschemiaCardiovascularOct 2027
NCT05854615Stempeucel®Phase 4Critical Limb IschemiaCardiovascularOct 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

TR Therapeutics Kerecis AOTI Beijing Inno Medicine Nectero Medical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.